7.38 USD
+0.48 (+6.96%)
7.2003 USD
-0.18 (-2.43%)
MYGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. MYGN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MYGN had positive earnings in the past year.
MYGN had a negative operating cash flow in the past year.
In the past 5 years MYGN always reported negative net income.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -55.01%, MYGN is in line with its industry, outperforming 45.61% of the companies in the same industry.
With a Return On Equity value of -107.43%, MYGN perfoms like the industry average, outperforming 44.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| ROIC | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYGN has a better Gross Margin (70.36%) than 81.31% of its industry peers.
In the last couple of years the Gross Margin of MYGN has declined.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYGN has more shares outstanding
Compared to 5 years ago, MYGN has more shares outstanding
Compared to 1 year ago, MYGN has a worse debt to assets ratio.
2.2 Solvency
MYGN has an Altman-Z score of 0.10. This is a bad value and indicates that MYGN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MYGN (0.10) is better than 62.43% of its industry peers.
A Debt/Equity ratio of 0.32 indicates that MYGN is not too dependend on debt financing.
MYGN's Debt to Equity ratio of 0.32 is on the low side compared to the rest of the industry. MYGN is outperformed by 69.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.1 |
ROIC/WACCN/A
WACC8.48%
2.3 Liquidity
A Current Ratio of 2.33 indicates that MYGN has no problem at all paying its short term obligations.
MYGN's Current ratio of 2.33 is on the low side compared to the rest of the industry. MYGN is outperformed by 70.65% of its industry peers.
MYGN has a Quick Ratio of 2.12. This indicates that MYGN is financially healthy and has no problem in meeting its short term obligations.
MYGN has a Quick ratio of 2.12. This is in the lower half of the industry: MYGN underperforms 71.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
MYGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.29%.
Measured over the past years, MYGN shows a very strong growth in Earnings Per Share. The EPS has been growing by 86.63% on average per year.
The Revenue has been growing slightly by 0.21% in the past year.
MYGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.32% yearly.
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
3.2 Future
Based on estimates for the next years, MYGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.46% on average per year.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 3.19% on average per year.
EPS Next Y-96.38%
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
EPS Next 5Y17.46%
Revenue Next Year-2.05%
Revenue Next 2Y1.74%
Revenue Next 3Y3.07%
Revenue Next 5Y3.19%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 147.60, MYGN can be considered very expensive at the moment.
Based on the Price/Earnings ratio, MYGN is valued cheaper than 88.60% of the companies in the same industry.
When comparing the Price/Earnings ratio of MYGN to the average of the S&P500 Index (25.45), we can say MYGN is valued expensively.
MYGN is valuated quite expensively with a Price/Forward Earnings ratio of 70.30.
Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 88.22% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, MYGN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 147.6 | ||
| Fwd PE | 70.3 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MYGN's earnings are expected to grow with 18.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
5. Dividend
5.1 Amount
No dividends for MYGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.38
+0.48 (+6.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.36%
Inst Owner Change-0.3%
Ins Owners2.62%
Ins Owner Change7.93%
Market Cap687.89M
Revenue(TTM)825.30M
Net Income(TTM)-400.50M
Analysts53.68
Price Target8.13 (10.16%)
Short Float %7.96%
Short Ratio5.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)363.83%
Min EPS beat(2)100%
Max EPS beat(2)627.66%
EPS beat(4)3
Avg EPS beat(4)193.66%
Min EPS beat(4)-2.9%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)222.43%
EPS beat(12)10
Avg EPS beat(12)156.03%
EPS beat(16)13
Avg EPS beat(16)126.64%
Revenue beat(2)1
Avg Revenue beat(2)0.96%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)3.49%
Revenue beat(4)1
Avg Revenue beat(4)-1.19%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.37%
Revenue beat(12)6
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)-0.17%
PT rev (1m)11.28%
PT rev (3m)11.28%
EPS NQ rev (1m)-1020%
EPS NQ rev (3m)-608.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.88%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 147.6 | ||
| Fwd PE | 70.3 | ||
| P/S | 0.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.85 | ||
| P/tB | 4.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.05
EY0.68%
EPS(NY)0.1
Fwd EY1.42%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS8.85
BVpS4
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.36% | ||
| FCFM | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 48.14% | ||
| Cap/Sales | 3.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 0.1 |
F-Score5
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-96.38%
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
EPS Next 5Y17.46%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
Revenue Next Year-2.05%
Revenue Next 2Y1.74%
Revenue Next 3Y3.07%
Revenue Next 5Y3.19%
EBIT growth 1Y13.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.33%
EBIT Next 3Y42.66%
EBIT Next 5Y15.6%
FCF growth 1Y78.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.09%
OCF growth 3YN/A
OCF growth 5YN/A
MYRIAD GENETICS INC / MYGN FAQ
What is the ChartMill fundamental rating of MYRIAD GENETICS INC (MYGN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MYGN.
Can you provide the valuation status for MYRIAD GENETICS INC?
ChartMill assigns a valuation rating of 2 / 10 to MYRIAD GENETICS INC (MYGN). This can be considered as Overvalued.
Can you provide the profitability details for MYRIAD GENETICS INC?
MYRIAD GENETICS INC (MYGN) has a profitability rating of 2 / 10.
How financially healthy is MYRIAD GENETICS INC?
The financial health rating of MYRIAD GENETICS INC (MYGN) is 3 / 10.